NO20000579L - Heparin-bindende vekstfaktor (HBGF) -polypeptider - Google Patents

Heparin-bindende vekstfaktor (HBGF) -polypeptider

Info

Publication number
NO20000579L
NO20000579L NO20000579A NO20000579A NO20000579L NO 20000579 L NO20000579 L NO 20000579L NO 20000579 A NO20000579 A NO 20000579A NO 20000579 A NO20000579 A NO 20000579A NO 20000579 L NO20000579 L NO 20000579L
Authority
NO
Norway
Prior art keywords
polypeptides
hbgf
growth factor
heparin
hbgfs
Prior art date
Application number
NO20000579A
Other languages
English (en)
Other versions
NO20000579D0 (no
Inventor
David A Brigstock
Paul A Harding
Original Assignee
Childrens Hosp Res Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hosp Res Foundation filed Critical Childrens Hosp Res Foundation
Publication of NO20000579D0 publication Critical patent/NO20000579D0/no
Publication of NO20000579L publication Critical patent/NO20000579L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Hovedsakelig rene heparin-bindende vekstfaktorpolypeptider (HBGF'er), nukleinsyrer som koder for HBGF'ene og antistoffer som binder til HBGF'ene i den foreliggende oppfinnelsen er tilveiebragt. HBGF-polypeptidene er nyttige i fremgangsmåter for induksjon av ben-, brusk- og vevsdannelse, vekst og utvikling av endometriet og for å akselerere sårtilheling.
NO20000579A 1997-08-07 2000-02-04 Heparin-bindende vekstfaktor (HBGF) -polypeptider NO20000579L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/908,526 US5876730A (en) 1997-08-07 1997-08-07 Heparin-binding growth factor (HBGF) polypeptides
PCT/US1998/016423 WO1999007407A1 (en) 1997-08-07 1998-08-06 Heparin-binding growth factor (hbgf) polypeptides

Publications (2)

Publication Number Publication Date
NO20000579D0 NO20000579D0 (no) 2000-02-04
NO20000579L true NO20000579L (no) 2000-02-25

Family

ID=25425931

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000579A NO20000579L (no) 1997-08-07 2000-02-04 Heparin-bindende vekstfaktor (HBGF) -polypeptider

Country Status (15)

Country Link
US (3) US5876730A (no)
EP (1) EP1003545B1 (no)
JP (2) JP4638027B2 (no)
CN (1) CN1276729A (no)
AT (1) ATE395927T1 (no)
AU (1) AU744585B2 (no)
BR (1) BR9811861A (no)
CA (1) CA2299411A1 (no)
DE (1) DE69839516D1 (no)
DK (1) DK1003545T3 (no)
ES (1) ES2307322T3 (no)
IL (1) IL134330A0 (no)
NO (1) NO20000579L (no)
PT (1) PT1003545E (no)
WO (1) WO1999007407A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562618B1 (en) 1997-12-25 2003-05-13 Japan Tobacco, Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
CA2346406C (en) * 1998-10-06 2009-02-17 Anton Wellstein Detection of pleiotrophin
US7141384B1 (en) 1998-10-06 2006-11-28 Georgetown University Detection of pleiotrophin
JP4722290B2 (ja) * 1998-12-14 2011-07-13 ユニバーシティー オブ マイアミ 結合組織成長因子（ｃｔｇｆ）断片とそれを用いた方法および使用
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
AU2001288392A1 (en) 2000-08-30 2002-03-13 University Of Delaware Delivery system for heparin-binding growth factors
US7297343B2 (en) * 2001-07-31 2007-11-20 Biosurface Engineering Technologies, Inc. Bioactive medical films
FR2828104B1 (fr) * 2001-08-01 2005-06-24 Chu Montpellier Utilisation d'inhibiteurs du facteur de croissance epidermique liant l'heparine ou d'inhibiteurs de ses recepteurs pour la preparation de medicaments utiles pour traiter le myelome
US20030113816A1 (en) * 2001-09-18 2003-06-19 Weitz Stephen L. Methods of assaying connective tissue growth factor
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
GB0225197D0 (en) * 2002-10-30 2002-12-11 Univ Sheffield Surface
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
WO2005033136A1 (en) * 2003-09-29 2005-04-14 Children's Hospital, Inc. Unique integrin binding site in connective tissue growth factor (ctgf)
CN101884789A (zh) 2004-02-11 2010-11-17 法布罗根股份有限公司 Ctgf作为糖尿病肾病的治疗靶点
CA2565070A1 (en) 2004-04-28 2005-11-24 Fibrogen, Inc. Anti-ctgf agents for the treatment of pancreatic cancer
DE102004021872B3 (de) 2004-05-04 2005-12-22 Infineon Technologies Ag Chipkarte, Verfahren zum Herstellen einer Chipkarte und elektrisch leitfähiges Kontaktierungselement
US20070049739A1 (en) * 2005-08-30 2007-03-01 Biomet Manufacturing Corp. Method and system for extracting blood-derived growth factors
US8946172B2 (en) * 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
MX2011002143A (es) 2008-08-25 2011-07-20 Excaliard Pharmaceuticals Inc Oligonucleotidos antisentido dirigidos contra el factor de crecimiento del tejido conectivo y usos de los mismos.
CN101497656B (zh) * 2009-03-09 2012-08-15 东南大学 与整合素αvβ3具有高结合活性的多肽及其应用
CN102666587A (zh) 2009-07-02 2012-09-12 菲布罗根有限公司 用于治疗肌营养不良的方法
US9102721B2 (en) 2011-01-21 2015-08-11 Fibrogen, Inc. Therapeutic method
MX365647B (es) 2011-02-02 2019-06-10 Excaliard Pharmaceuticals Inc El uso de compuestos antisentido dirigidos al factor de crecimiento del tejido conectivo (ctgf) para tratar queloides o cicatrices hipertroficas.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235042A (en) * 1984-02-29 1993-08-10 The Children's Medical Center Corporation Endothelial cell growth factor
US4868113A (en) * 1986-03-03 1989-09-19 Rorer Biotechnology, Inc. Recombinant DNA vector encoding human endothelial cell growth factor
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85018A0 (en) * 1988-01-03 1988-06-30 Orgenics Ltd Stable chromogenic substrate mixture of indoxyl phosphate and tetrazolium salt,method of making and using same in biological and diagnostic assays
US5225326A (en) * 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
JPH06502538A (ja) 1990-10-16 1994-03-24 ザ　チルドレンズメディカルセンターコーポレーション 上皮細胞成長因子（ｅｇｆ）との相同性をもつヘパリン結合性マイトジェン
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US5770209A (en) 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5596090A (en) * 1992-07-24 1997-01-21 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human VCAM-1 RNA
JPH10502534A (ja) 1994-07-12 1998-03-10 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド 結合組織増殖因子−２
US5646115A (en) * 1994-10-07 1997-07-08 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
US5607918A (en) * 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof

Also Published As

Publication number Publication date
AU744585B2 (en) 2002-02-28
US20110160445A1 (en) 2011-06-30
CN1276729A (zh) 2000-12-13
AU8696298A (en) 1999-03-01
WO1999007407A1 (en) 1999-02-18
US7897732B2 (en) 2011-03-01
DK1003545T3 (da) 2008-08-25
JP4638027B2 (ja) 2011-02-23
BR9811861A (pt) 2000-08-15
JP2009254370A (ja) 2009-11-05
JP2001513334A (ja) 2001-09-04
EP1003545A1 (en) 2000-05-31
US20010007019A1 (en) 2001-07-05
EP1003545B1 (en) 2008-05-21
DE69839516D1 (de) 2008-07-03
CA2299411A1 (en) 1999-02-18
NO20000579D0 (no) 2000-02-04
WO1999007407A9 (en) 1999-05-06
EP1003545A4 (en) 2002-03-06
ATE395927T1 (de) 2008-06-15
PT1003545E (pt) 2008-08-13
ES2307322T3 (es) 2008-11-16
IL134330A0 (en) 2001-04-30
US5876730A (en) 1999-03-02

Similar Documents

Publication Publication Date Title
NO20000579L (no) Heparin-bindende vekstfaktor (HBGF) -polypeptider
NO995044L (no) Osteoprotegerinbindende proteiner og reseptorer
MX9206315A (es) Heterodimeros recombinantes de proteinas morfogenicas de hueso, composiciones de estos y metodos para su uso.
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
CY1112101T1 (el) Νευροτροφικοι παραγοντες
NZ330897A (en) Human trk receptors and neurotropic factor inhibitors
ME00185B (me) Specifični agensi koji vezuju humani angiopoetin-2
ATE265529T1 (de) Bmp-10 zusammensetzungen
ATE234124T1 (de) Verfahren zur herstellung von wirkstoffhaltigen knochenzementen
DE69032598D1 (de) Zusammensetzungen und methoden zur synthese des b-rezeptors für das natriuretische protein und verwendungsmethoden
PT804562E (pt) Factor 2 de crescimento de tecido conjuntivo
PT783521E (pt) Compostos polipeptidos que contem d-2-alquiltriptofano capazes de promover a libertacao da hormona do crescimento
ATE107859T1 (de) Verwendung von antiprogestomimetika zur stimulierung des eisprungs.
DE69533044D1 (de) FÜR DEN TYP II-MORPHOGENETISCHEN-KNOCHENPROTEIN-REZEPTOR KODIERENDE cDNS
ATE263239T1 (de) Produkte des keratinocyten-wachstumsfaktors 2 (kgf-2)
SE9602822D0 (sv) New receptor
IL129139A0 (en) Vertebrate smoothened proteins
DE69315989T2 (de) Aminoterminale prokollagen 1(i) peptide
ATE293163T1 (de) Cyclin e spezifische konstrukte und komplexe
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
SE9604439D0 (sv) New receptor
ES2186501A1 (es) Factor de crecimiento fibroblastico basico con un dominio de union especifico a colegeno.
EA200100110A1 (ru) Нейротрофические факторы
DE59611353D1 (de) Transketolase-verwandtes protein
ATE134989T1 (de) N-trityl asparaginsäurederivate zur herstellung von phosphonat nmda antagonisten

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application